Study guide

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care

Key Takeaways Explain This Topic AI

Area V, covering ethics, evidence-based practice, continuous quality improvement and policy advocacy, carries 5% of the CARN-AP blueprint, about 7 to 8 items.

Quality improvement seeks to improve care in a local setting and does not require IRB review, while research seeks generalizable knowledge and does.

The Plan-Do-Study-Act cycle drives small, rapid, repeated tests of change rather than a single large implementation.

Structure, process and outcome measures answer different questions, and balancing measures detect harm caused by the improvement itself.

Retention in treatment and medication continuity are more actionable addiction quality measures than abstinence rates, which are heavily influenced by case mix.

Last updated: September 2026

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care

Quick Answer: Activity Area V — incorporate ethical principles and evidence-based practice to promote clinical excellence, optimal outcomes, continuous quality improvement and policy advocacy — is 5% of the CARN-AP (7 to 8 items) but contains 26 activity statements , the most of any area. Quality improvement improves care in a local setting and generally does not require IRB review; research generates generalizable knowledge and does. Improvement work runs on Plan-Do-Study-Act (PDSA) cycles and uses structure, process, outcome and balancing measures.

1. Quality Improvement Versus Research

  • Dimension Quality improvement Research
  • Purpose Improve a process in this setting Produce generalizable knowledge
  • Design Iterative; the intervention changes as you learn Fixed protocol
  • Participants Everyone receiving care in the setting Recruited and consented subjects
  • Risk Usually no more than standard care May exceed standard care
  • Oversight Institutional QI structure; IRB review generally not required IRB review required
  • Publication May be published; SQUIRE reporting guideline applies CONSORT, STROBE, PRISMA as applicable

The boundary blurs when a QI project randomizes patients, withholds standard care, or is designed from the outset to produce findings intended for other institutions. When in doubt, ask the IRB for a determination rather than deciding unilaterally — that consultation is itself the defensible answer on an exam item.

2. The Model for Improvement and PDSA

Three questions precede any cycle:

What are we trying to accomplish? A specific, measurable, time-bound aim. "Increase the proportion of patients with opioid use disorder who leave the hospital with a buprenorphine prescription from 22% to 60% within six months."

How will we know a change is an improvement? The measures.

What changes can we make that will result in improvement? The change ideas.

Then PDSA :

  • Phase Content
  • Plan Define the test, who does what by when, what data will be collected, and the prediction
  • Do Run the test on a deliberately small scale — one clinician, one shift, five patients
  • Study Compare results with the prediction; ask what was learned, including from failure
  • Act Adopt, adapt, or abandon; then start the next cycle

The most common error is scale. Teams launch a unit-wide protocol as the first test and discover a fatal flaw after a month of wasted effort. A first PDSA should be small enough to run tomorrow.

3. Choosing Measures

Type Question it answers Addiction example

Structure Do we have the capacity? Number of clinicians credentialed to prescribe buprenorphine; naloxone stocked on every unit

Process Are we doing the right things? Percentage of admitted patients screened with a validated tool; percentage of patients with OUD offered medication

Outcome Did the patient do better? 30-day treatment retention; 90-day medication continuity; readmission; non-fatal overdose

Balancing Did we cause harm elsewhere? Emergency department length of stay after adding a screening protocol; nursing time displaced from other tasks

Process measures move first. An improvement team that tracks only overdose mortality will see nothing for a year and lose momentum. Track the process measure you control weekly and the outcome measure quarterly.

Addiction-specific measures worth knowing

Initiation and Engagement of Substance Use Disorder Treatment (IET): a widely used measure of whether a patient initiates treatment within 14 days of a new diagnosis and engages with two or more further encounters within 34 days of initiation.

Continuity of pharmacotherapy for opioid use disorder: the proportion of patients with at least 180 days of continuous medication — a strong, actionable measure.

Follow-up after emergency department visit for substance use.

Naloxone co-prescribing rate for patients at elevated overdose risk.

Why abstinence is a poor primary measure: abstinence rates are dominated by case mix. A program that admits the sickest patients will look worst on abstinence and may be delivering the best care. Retention and medication continuity are less gameable and more directly modifiable.

4. Displaying and Interpreting Data

Run charts and statistical process control charts distinguish real signal from normal variation. A single month's change is almost always noise.

Common cause variation is inherent to the process and requires a process change. Special cause variation has an identifiable external explanation and requires investigating that cause. Reacting to common cause variation as though it were special cause — "why were numbers down in March?" — wastes effort and demoralizes teams.

Stratify by race, ethnicity, language, insurance and sex. An aggregate improvement can conceal a widening disparity, and in addiction care, disparities in who is offered medication are well documented.

5. From Individual Frustration to System Change

The practice analysis lists "uses the results of quality improvement to initiate changes in nursing practice and the health care delivery system" and "differentiates outcomes that require care process interventions from those that require system-level interventions." The distinction is practical:

  • Problem Level Fix
  • One nurse does not know how to score CIWA-Ar Care process Individual education

Most nurses score CIWA-Ar inconsistently System Standardized training, an embedded scoring tool, and audit with feedback

A patient left before buprenorphine induction Care process Review that case

A third of patients leave before induction because pharmacy takes four hours to deliver the first dose System Stock buprenorphine as a floor medication or use an override pathway

The recurring exam pattern: when a problem repeats across clinicians and patients, the correct answer is a system-level intervention , not more individual education.